What is mixed phenotype acute leukaemia?
Mixed phenotype acute leukaemia (MPAL) is a rare type of acute leukaemia in which the leukaemia cells show features of more than one type of blood cell at the same time.
Most acute leukaemias are clearly either myeloid (acute myeloid leukaemia, AML) or lymphoid (acute lymphoblastic leukaemia, ALL). In MPAL, the leukaemia cells, called blasts, carry markers of both the myeloid line and a lymphoid line, either B cells or T cells. Sometimes two separate groups of blasts are present, one of each type.
Because it does not fit neatly into either group, MPAL belongs to a family called acute leukaemias of ambiguous lineage. It accounts for about 2-5% of all acute leukaemias and affects both children and adults (Wolach and Stone, 2015; Khoury et al., 2022).
Like other acute leukaemias, MPAL develops quickly. It crowds out healthy cells in the bone marrow, leading to anaemia, infections and bleeding, and it needs urgent treatment.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of disease | Acute leukaemia with features of more than one blood cell line |
| How common | About 2-5% of acute leukaemias |
| Who is affected | Children and adults; slightly more common in males |
| Most common forms | B/myeloid and T/myeloid |
| Important genetic types | BCR::ABL1 (Philadelphia chromosome), KMT2A rearrangement, ZNF384 rearrangement |
| Key symptoms | Tiredness, infections, bruising, bleeding, fever, bone pain |
| Main treatment | Intensive chemotherapy, usually ALL-type; often a stem cell transplant in adults |
| Outlook | Better in children (most are cured) than in adults |
2. Types of MPAL
The World Health Organization (WHO) and the International Consensus Classification group MPAL by genetic changes first, then by the mix of cell lines (Khoury et al., 2022).
| Type | Main features |
|---|---|
| MPAL with BCR::ABL1 | Has the Philadelphia chromosome; mostly adults; treated with a tyrosine kinase inhibitor plus chemotherapy |
| MPAL with KMT2A rearrangement | Common in infants; often B/monocytic |
| MPAL with ZNF384 rearrangement | Mostly children; usually B/myeloid |
| Acute leukaemia of ambiguous lineage with BCL11B rearrangement | Often T/myeloid; a recently recognised group |
| B/myeloid MPAL, not otherwise specified | Blasts show B-cell and myeloid markers |
| T/myeloid MPAL, not otherwise specified | Blasts show T-cell and myeloid markers |
| Rare types | For example B/T MPAL or triple lineage |
Related conditions
| Condition | Difference from MPAL |
|---|---|
| Acute undifferentiated leukaemia | Blasts show no clear lineage at all |
| AML with some lymphoid markers | Mainly myeloid; does not meet MPAL criteria |
| ALL with some myeloid markers | Mainly lymphoid; treated as ALL |
| Early T-cell precursor ALL | Immature T-cell leukaemia; can overlap with T/myeloid MPAL |
3. Causes and risk factors
The cause of MPAL is usually unknown. It develops when a very early blood-forming cell acquires genetic changes that let it grow out of control while keeping the ability to show features of several lineages (Alexander et al., 2018).
| Factor | Notes |
|---|---|
| Acquired gene changes | Such as BCR::ABL1, KMT2A, ZNF384, PHF6 and others; these are not inherited |
| Previous chemotherapy or radiotherapy | A small number of cases follow earlier cancer treatment |
| Age | Infants (often KMT2A) and older adults (often BCR::ABL1) |
| Inherited conditions | Rarely linked with conditions that raise leukaemia risk in general |
MPAL is not infectious. It is not caused by anything a person did or did not do, and it is not usually passed on in families.
4. How does it look
In the blood and bone marrow
| Feature | What doctors see |
|---|---|
| Blood count | High, normal or low white cell count; often low red cells and platelets |
| Blood film | Blasts may be visible in the blood |
| Bone marrow | Packed with blasts, usually more than 20% of cells |
| Blast appearance | Some look like lymphoblasts, others like myeloblasts; sometimes two distinct groups |
Under the microscope and on flow cytometry
The diagnosis rests on flow cytometry, a test that identifies proteins on and inside the blasts. Specific markers prove each lineage (Khoury et al., 2022):
| Lineage | Key markers |
|---|---|
| Myeloid | Myeloperoxidase (MPO), or monocytic markers such as CD11c, CD14, CD64 and lysozyme |
| T cell | Cytoplasmic CD3 at a strong level |
| B cell | Strong CD19 with CD79a, cytoplasmic CD22 or CD10; or weaker CD19 with several of these |
Visible signs
Others may notice that the person looks pale and tired, has bruises that appear easily, or has small red or purple spots on the skin called petechiae.
Some people have swollen lymph nodes in the neck, armpits or groin, or a swollen abdomen from an enlarged liver or spleen. In T/myeloid MPAL, a mass in the chest can cause swelling of the face and neck.
5. Symptoms
Symptoms usually appear over days or weeks.
Symptoms from low blood counts
| Low blood count | Symptoms |
|---|---|
| Low red cells (anaemia) | Tiredness, weakness, pale skin, breathlessness, fast heartbeat |
| Low normal white cells | Frequent or severe infections, fever, mouth ulcers |
| Low platelets | Easy bruising, nosebleeds, bleeding gums, heavy periods, tiny red spots |
Other symptoms
- Fever and night sweats
- Bone or joint pain, which is common in children
- Loss of appetite and weight loss
- Swollen lymph nodes
- Fullness or pain in the left upper abdomen from an enlarged spleen
- Breathlessness or cough if there is a mass in the chest
- Headache, vomiting or problems with vision if the leukaemia affects the brain and spinal fluid
When to seek medical advice
See a doctor promptly for unexplained tiredness, bruising, frequent infections or bone pain that does not settle.
Seek urgent help for fever with chills, heavy bleeding, severe breathlessness, or swelling of the face and neck.
6. Diagnosis
| Test | Purpose |
|---|---|
| Full blood count and blood film | Shows low blood counts and blasts |
| Bone marrow aspirate and biopsy | Confirms acute leukaemia |
| Flow cytometry | Identifies the lineage markers that define MPAL |
| Cytogenetics and FISH | Look for the Philadelphia chromosome, KMT2A and other changes |
| Molecular testing (PCR or sequencing) | Finds gene fusions and mutations |
| Lumbar puncture | Checks for leukaemia in the spinal fluid |
| Chest X-ray or CT | Looks for a mass in the chest |
| Clotting tests, kidney and liver tests | Check general health before treatment |
| Tissue typing (HLA typing) | Prepares for a possible stem cell transplant |
MPAL diagnosis can be difficult, and samples are usually reviewed by specialist laboratories. A clear diagnosis matters because the choice of treatment depends on it.
7. Treatment
MPAL is treated in specialist leukaemia centres. Because it is rare, there are few clinical trials, and treatment is based mainly on large retrospective studies and expert consensus (Wolach and Stone, 2015; Alexander and Orgel, 2021).
Choosing the chemotherapy
Studies suggest that ALL-type chemotherapy often works as well as or better than AML-type chemotherapy for most people with MPAL, and it is usually less toxic (Matutes et al., 2011; Hrusak et al., 2018).
| Treatment phase | What happens |
|---|---|
| Induction | Intensive chemotherapy to clear blasts from the bone marrow; usually ALL-type |
| Consolidation and intensification | Further courses to destroy remaining leukaemia cells |
| CNS-directed treatment | Chemotherapy into the spinal fluid to prevent or treat spread to the brain |
| Maintenance | Lower-dose tablets and injections, often for about two years, in ALL-type schedules |
| Switch to AML-type treatment | Considered if the leukaemia does not respond to ALL-type induction |
Targeted treatment
| Situation | Option |
|---|---|
| BCR::ABL1 (Philadelphia-positive) | A tyrosine kinase inhibitor such as imatinib, dasatinib or ponatinib added to chemotherapy |
| Other targetable changes | Clinical trials of targeted drugs, for example menin inhibitors in KMT2A-rearranged leukaemia |
| Relapse or resistance | Immunotherapies such as blinatumomab or CAR-T cells may be used in B/myeloid MPAL in some centres |
Measuring response
Doctors measure minimal residual disease (MRD), the tiny amount of leukaemia left after treatment that cannot be seen under the microscope. MRD results help decide whether further, more intensive treatment is needed (Oberley et al., 2020).
Stem cell transplant
| Group | Approach |
|---|---|
| Adults | An allogeneic stem cell transplant from a donor is commonly recommended in first remission |
| Children | Transplant is usually reserved for those with persisting MRD or a poor response (Hrusak et al., 2018) |
What to expect during induction
Induction usually takes about four to six weeks and is often given in hospital or with very frequent day-unit visits. A central line (a thin tube into a large vein) is usually placed so that chemotherapy can be given and blood taken without repeated needles.
During this time, blood counts fall very low. Most people need blood and platelet transfusions, and many need antibiotics for fever. A bone marrow test at the end of induction shows whether the leukaemia is in remission and measures MRD.
Older and less fit adults
Intensive treatment and transplant are not suitable for everyone. For older adults or people with other serious illnesses, doctors may suggest less intensive treatment, such as lower-dose chemotherapy, a tyrosine kinase inhibitor with steroids in BCR::ABL1-positive MPAL, or venetoclax-based combinations that are used in AML. Supportive care to control symptoms is always part of treatment.
Side effects of treatment
| Side effect | Notes |
|---|---|
| Infections | The biggest risk during treatment |
| Hair loss, nausea and mouth sores | Common and usually temporary |
| Tiredness | Can last months |
| Fertility problems | Discuss fertility preservation before treatment where possible |
| Graft-versus-host disease | A possible complication of a donor transplant |
8. Outlook (prognosis)
The outlook depends on age, genetic type and response to treatment.
| Group | Approximate outlook |
|---|---|
| Children treated with ALL-type therapy | Most are long-term survivors, with event-free survival around 70-80% in large studies (Hrusak et al., 2018) |
| Adults | About a third to a half are long-term survivors; in one series of 100 patients, mostly adults, 37% were alive at 5 years (Matutes et al., 2011); results are better after transplant in first remission |
| BCR::ABL1-positive MPAL | Improved by tyrosine kinase inhibitors |
| KMT2A-rearranged MPAL in infants | Poorer outlook |
| MRD-negative after induction | Better outlook |
Outcomes have improved as doctors have learned that ALL-type therapy suits most people with MPAL, and as targeted drugs and transplant methods have advanced.
9. Long-term effects and follow-up
After treatment, people are followed up for several years with blood tests and check-ups.
| Possible late effect | Follow-up |
|---|---|
| Heart problems | From anthracycline drugs; heart scans |
| Growth and learning | Monitoring in children |
| Fertility and hormones | Hormone tests and specialist advice |
| Bone health | From steroids; bone scans in some |
| Second cancers | Rare; regular check-ups |
Relapse
If MPAL comes back, treatment depends on the earlier treatment, the time since remission and the leukaemia’s markers at relapse. Options include different chemotherapy, immunotherapy directed at B-cell markers, targeted drugs and a stem cell transplant or second transplant. Clinical trials are especially important at this stage.
10. Living with MPAL
- Report fever immediately; infections need urgent treatment during chemotherapy
- Keep a thermometer at home and know your hospital’s emergency number
- Wash hands often and avoid people with infections
- Eat as well as possible; a dietitian can help
- Stay as active as you feel able
- Ask about emotional support for yourself and your family
- Ask about school or work support during long treatment
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is MPAL a mix of two leukaemias? | Not exactly. It is one leukaemia whose cells show features of more than one blood cell line |
| Is MPAL treated like ALL or AML? | Usually like ALL, with changes depending on response and genetic type |
| Will I need a stem cell transplant? | Often in adults; less often in children |
| Is it inherited? | Usually not |
| Can MPAL be cured? | Yes, many children and a good number of adults are cured |
| How long does treatment take? | ALL-type treatment usually lasts around two to three years including maintenance |
12. Questions to ask your care team
- What type of MPAL do I have, and which genetic changes were found?
- Will I have ALL-type or AML-type chemotherapy?
- What is my MRD result, and what does it mean?
- Do you recommend a stem cell transplant?
- Is there a targeted drug for my type of leukaemia?
- Are there clinical trials I could join?
- How can I protect my fertility?
Resources
- Alexander, T.B. et al. (2018) ‘The genetic basis and cell of origin of mixed phenotype acute leukaemia’, Nature, 562(7727), pp. 373-379.
- Alexander, T.B. and Orgel, E. (2021) ‘Mixed phenotype acute leukemia: current approaches to diagnosis and treatment’, Current Oncology Reports, 23(2), p. 22.
- Hrusak, O. et al. (2018) ‘International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia’, Blood, 132(3), pp. 264-276.
- Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms’, Leukemia, 36(7), pp. 1703-1719.
- Matutes, E. et al. (2011) ‘Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification’, Blood, 117(11), pp. 3163-3171.
- Oberley, M.J. et al. (2020) ‘Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study’, Leukemia, 34(7), pp. 1741-1750.
- Orgel, E. et al. (2020) ‘Mixed-phenotype acute leukemia: a cohort and consensus research strategy from the Children’s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force’, Cancer, 126(3), pp. 593-601.
- Wolach, O. and Stone, R.M. (2015) ‘How I treat mixed-phenotype acute leukemia’, Blood, 125(16), pp. 2477-2485.
- Wolach, O. and Stone, R.M. (2020) ‘Optimal therapeutic strategies for mixed phenotype acute leukemia’, Current Opinion in Hematology, 27(2), pp. 95-102.
Prepared by the editorial team, October 2026.